Report from Annual General Meeting of Vitrolife AB (publ)
GÖTEBORG, Sweden, April 27, 2023 /PRNewswire/ -- At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:
Resolution in accordance with the Board's proposed dividend of SEK 0.85 per share for the financial year 2022. Tuesday 2 May, 2023 was adopted as the record day.
Re-election of Board members Henrik Blomquist, Lars Holmqvist, Vesa Koskinen, Pia Marions, Jón Sigurdsson and Karen Lykke Sřrensen, in accordance with the election committee's proposal. Henrik Blomquist was elected Chairman of the Board.
Remuneration to the members of the Board shall be totaling SEK 3,600,000, of which SEK 1,200,000 to the Chairman of the Board, SEK 400,000 to each of the other members of the Board, SEK 100,000 to the Chairman of the Audit Committee, SEK 100,000 to the Chairman of the Remuneration Committee and SEK 50,000 to the other members of these committees.
The board's proposal for Amendment of the Articles of Association was approved.
Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
Resolution to implement a share-based incentive program including issue of a maximum number of 229,500 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.
Gothenburg, April 27, 2023 VITROLIFE AB (publ) The Board
The information was submitted for publication, through the agency of the contact persons set out above, at 27-04-2023 17:15 CET.
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional favorable safety and efficacy data from the company's ongoing Phase 1b/2 clinical trial...
Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, and AmplifyBio, a rapidly growing contract development and manufacturing organization, today announced the launch of a...
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois...
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltaceltm (KB-GDT-01), Kiromic's allogeneic,...
JPMA Cares, the nonprofit foundation of the juvenile products industry, announced it's launching a Safe Sleep Campaign in partnership with Cribs for Kids, First Candle, and Safe Kids Worldwide. The campaign aims to deliver easy-to-understand,...
MedISAO, an organization composed of members of the medical device manufacturer community dedicated to improving medical device security through education, awareness, and advocacy, announced today its endorsement by the Food and Drug Administration...